×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 北京... [6]
吉林大学白求恩第一医... [3]
山东大学 [1]
复旦大学上海医学院 [1]
内容类型
会议论文 [11]
发表日期
2018 [4]
2017 [5]
2015 [1]
2013 [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共11条,第1-10条
帮助
限定条件
内容类型:会议论文
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
会议论文
作者:
Senkus-Konefka, E.
;
Domchek, S. M.
;
Im, S. A.
;
Xu, B.
;
Armstrong, A.
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2019/12/05
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
会议论文
EUROPEAN JOURNAL OF CANCER, 2018-04-01
作者:
Senkus-Konefka, E.
;
Domchek, S. M.
;
Im, S. A.
;
Xu, B.
;
Armstrong, A.
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2020/01/03
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
会议论文
CANCER RESEARCH, 2018-02-01
作者:
Domchek, Susan M.
;
Robson, Mark
;
Im, Seock-Ah
;
Senkus, Elzbieta
;
Xu, Binghe
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2020/01/03
Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
会议论文
ANNALS OF ONCOLOGY, 2018-10-01
作者:
Liu, Y-Z.
;
Hodgson, D.
;
Locker, G.
;
Lai, Z.
;
Balcerzak, D.
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2020/01/03
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
会议论文
作者:
Robson, Mark E.
;
Im, Seock-Ah
;
Senkus, Elzbieta
;
Xu, Binghe
;
Domchek, Susan M.
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2019/12/05
OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician"s choice
会议论文
作者:
Runswick, S.
;
Robson, M.
;
Conte, P. F.
;
Im, S-A.
;
Senkus-Konefka, E.
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2019/12/05
OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's cho
会议论文
ANNALS OF ONCOLOGY, 2017-09-01
作者:
Robson, M.
;
Ruddy, K. J.
;
Im, S-A.
;
Senkus-Konefka, E.
;
Xu, B.
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2020/01/03
OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice
会议论文
ANNALS OF ONCOLOGY, 2017-09-01
作者:
Delaloge, S.
;
Conte, P. F.
;
Im, S-A.
;
Senkus-Konefka, E.
;
Xu, B.
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2020/01/03
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2017-05-20
作者:
Robson, Mark E.
;
Im, Seock-Ah
;
Senkus, Elzbieta
;
Xu, Binghe
;
Domchek, Susan M.
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2020/01/04
MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC)
会议论文
作者:
Im, S. -A.
;
Chow, L.
;
Shao, Z.
;
Tripathy, D.
;
Bardia, A.
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2019/12/19
©版权所有 ©2017 CSpace - Powered by
CSpace